The Lazarus Pharmaceuticals, LLC leadership team has extensive product development, commercial and venture capital experience. We will use this experience to identify promising candidates for further development and to obtain the necessary financing.

ALAN JOSLYN, PhD
Alan is a co-founder of Lazarus Pharmaceuticals. Currently, he is the CEO of Oragenics Pharmaceuticals. Previously, in association with Care Capital, a life sciences venture capital firm, he was Chief Executive Officer of Sentinella Pharmaceuticals, a privately held antibiotic company and CEO of Edusa Pharmaceuticals, a privately held GI company. Prior to his association with Care Capital he served as the President and Chief Executive Officer of Mt. Cook Pharma from 2007 to 2009, and as Senior Vice President of Research & Development at Penwest Pharmaceuticals from 2004 to 2007. From 1995 to 2004, he held a number of leadership positions within Johnson & Johnson, focusing on development of GI products including Propulsid®, Motilium®, Aciphex® and prucalopride. Alan received his B.S. in Medicinal Chemistry, B.A. in Biology and Ph.D. in Biochemical Pharmacology from the State University of New York at Buffalo.
JOSEPH SANGER, RPh, MBA
Joe is a co-founder and managing director of Lazarus Pharmaceuticals. He has over 25 years of experience in the pharmaceutical industry. After leaving as Global GI Franchise Leader at Johnson & Johnson in 2005, he founded GastroMIND, a business development consulting company specializing in identifying opportunities in the GI marketplace. Prior to starting his business development venture, he worked on and led both US and global GI teams at Johnson & Johnson, Glaxo and Schering Plough for Aciphex, Propulsid, Motilium, prucalopride and Zantac®. Joe holds a BS degree in pharmacy from Massachusetts College of Pharmacy and an MBA from Boston University.
TROY HAMILTON, PharmD, MBA
Troy joined as a board member in May 2019. He has more than 25 years of experience in the pharmaceutical, biotechnology, and healthcare industries. Currently, he is CEO of Ellodi Pharmaceuticals, a TPG Capital portfolio company. Previously, he was Global Head of Specialty Pharma at Adare Pharmaceuticals and held several executive and global commercial leadership roles at Synergy Pharmaceuticals, Shire Pharmaceuticals, and Johnson & Johnson. He also serves as a board member at metaMe Health, Inc. and board advisor at New Perspectives, Inc. Troy received his Bachelor of Science and Doctorate degrees in Pharmacy from the University of the Sciences in Philadelphia and his MBA from St. Joseph’s University.

Discover Innovative and Efficient Drug Development

Contact Us